Aligos Therapeutics Inc
Research Aligos Therapeutics Inc (ALGS) on Bullrun: market cap USD 46.59M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALGS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 46.59M
- Financial periodQ2 2026
- RevenueUSD 27.78M
- Net income-USD 1.50M
- Free cash flow-USD 24.95M
Valuation Snapshot
latest market cap is USD 46.59M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.19M | -USD 24.19M | -USD 82.94M | n/a | -2.45 | USD 18.30M | USD 5.25M | USD 53.55M |
| FY2024 | USD 3.61M | -USD 131.21M | -USD 80.87M | n/a | -20.94 | USD 37.00M | USD 8.38M | -USD 28.97M |
| FY2023 | USD 6.19M | -USD 87.68M | -USD 79.02M | n/a | -34.2 | USD 135.70M | USD 11.14M | USD 92.08M |
| FY2022 | USD 0 | -USD 96.05M | -USD 80.33M | n/a | -2.25 | USD 81.35M | USD 13.44M | USD 103.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 46.59M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 57.58M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 153.96M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 49.76M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 40.81M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 506.73M | n/a | n/a | n/a |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aligos Therapeutics Inc's market cap?
Aligos Therapeutics Inc's market capitalization is USD 46.59M.
What does Aligos Therapeutics Inc do?
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.